Zusammenfassung
Die Manifestation einer Neuritis nervi optici im Rahmen der Multiplen Sklerose (MS) ist seit den klassischen Arbeiten des Berliner Augenarztes W. Uhthoff (1890) sehr gut bekannt. In einer Analyse von 1271 Patienten zeigen Wikström et al. (1980), dass eine Optikusneuritis in 34,7% bei klinischer Erstmanifestation der MS und in 16,6% sogar als isoliertes Initialsymptom eruierbar ist. Diese Befunde konnten von weiteren Arbeitsgruppen bestätigt werden (Poser 1984, Paty u. Ebers 1998).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Beck RW, Cleary PA, Anderson MM et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581–588.
Beck RW, Cleary PA, Trobe JD et al. (1993 a) The effect of corticosteroids für acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764–1769.
Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufmann DI and Optic Neuritis Study Group (1993 b) Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group Arch Neurol 50:841–846.
Bradley WG, Whitty CWM (1968) Acute optic neuritis: prognosis for development of multiple sclerosis. J Neurol Neurosurg Psychiat 31:10–18.
Cleary PA, Beck RW, Anderson MM et al. (1993) Design, methods and conduct oft the Optic Neuritis Treatment Trial. Control Clin Trials 14:123–142.
Cohen MM, Lessell S, Wolf PA (1979) A prospective study of the risk of developing multiple sclerosis in uncomplicated optic neuritis. Neurol 29:208–213.
Comi G, Filippi M, Barkhof F et al. (2000) Interferon beta la (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study. Neurol 54(Suppl 3):A85–A86.
Comi G, Filippi M, Barkhof F et al. (2000) Effects of Interferon Beta-la (Rebif) in patients with acute neurological syndromes at high risk of developing clinically definite multiple sclerosis: A double-blind, multicentre european, randomised, double-blind, placebo controlled study (ETOMS). J Neurol 247(Suppl 3):217.
Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438.
Earl CJ, Martin B (1967) Prognosis of optic neuritis related to age. Lancet 1:74–76.
Fazekas F, Barkhof F, Filippi M et al. (1999) The contribution of mangnetic resonance imaging to the diagnosis of multiple sclerosis. Neurologie 53:448–456.
Ferguson B, Matyszak M, Esiri M, Perry V (1997) Axonal damage in multiple sclerosis lesions. Brain 120:393–399.
Frederiksen JL (1997) Bilateral acute optic neuritis: Propsective clinical, MRI, CSF, neuro- physiological and HLA findings. Neuro-opthalmol 17:175–183.
Freitag P, Radii EW, Kappos L (1999) Bildgebende Diagnostik bei der Multiplen Sklerose. In: Zettl UK, Mix E (Hrsg) Klinische Neuroimmunologie. Walter de Gruyter, Berlin New York, 121–134.
Guthoff R, Pauleikhoff D, Hingst V (1999) Bildgebende Diagnostik in der Augenheilkunde. Enke, Stuttgart.
Halliday AM, Halliday E, Kriss A et al. (1976) The pattern evoked potential in compressing of anterior viral pathways. Brain 99:357–374.
Hely MA, Mc Manis PG, Doran TJ et al. (1986) Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiat 49:1125–1130.
Hutchinson D, Solomon T, Moots RJ (2000) Devic’s neuromyelitis optica: a primary autoimmune disease? Rheumatol 39:215–217.
Jacobs LD, Kaba SE, Miller CM et al. (1997) Correlation of clinical, magnetic resonance imaging an cerebrospinal fluid findings in optic neuritis. Ann Neurol 41:392–398.
Jacobs LD, Beck RW, Simon JH et al. (2000) The effect of intramuscular interferon beta–la treatment initiated at the time of a first acute clinical demyelinianting event on the rate of developtment of clinically definite multiple sclerosis. New Engl J Med 343:898–904.
Kaufmann DI, Trobe JD, Eggenberger ER, Whitaker JN (2000) Practice paramerter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report oft the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:3039–3044.
Kesselring J (1997) Multiple Sklerose. 2. Aufl. Kohlhammer, Stuttgart Berlin Köln.
Kinnunen E (1983) The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand 68:371–377.
Kunesch E, Classen J, Benecke R (1999) Elektrophysiologische Diagnostik bei Autoimmun– erkrankungen des Nerven- und Muskelsystems. In: Zettl UK, Mix E (Hrsg) Klinische Neuroimmunologie. Walter de Gruyter, Berlin New York, 89–110.
Lee AG, Brazis PW (1998) Clinical pathways in neuro–opthalmology: An evidence–based approach. Thieme, New York.
Lehmitz R, Mix E, Zettl UK (1999) Liquorparameter bei entziindlichen Erkrankungen des Nervensystems. In: Zettl UK, Mix E (Hrsg) Klinische Neuroimmunologie. Walter de Gruyter, Berlin New York, 59–88.
Lucchinetti CF, Kiers L, O’Duffy A, Gomez MR, Cross S, Leavitt JA, O’Brien P, Rodriguez M (1997) Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 49:1413–1418.
Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34:162–168.
Matthews B (1998) Sympotoms and signs of multiple scleroris. In: Multiple Sclerosis. Churchill Livingstone, London Edinburgh New York Philadelphia Sydney Toronto.
Mc Donald WI (1983) Doyne lecture: The significance of optic neuritis. Trans Ophthal Soc UK 103:230–246.
Morrissey S, Miller D, Kendall B (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 116:135–146.
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (1999) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt 70:371–386.
Multiple Sklerose Therapie Konsens Gruppe (MSTKG) (2001) in Vorbereitung.
National Multiple Sclerosis Society of USA (NMSS) (1998) Disease management consensus statement. Internet www.nmss.org.
Oger J, Freedman M (1999) Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in multiple slerosis. Can J Neurol Sci 26:294.
Optic Neuritis Study Group (1991) The clinical profile of acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 109:1673–1678.
Optic Neuritis Study Group (1997 a) The 5–years risk of multiple sclerosis after opticus neuritis. Neurology 49:773–775, 1404–1413.
Optic Neuritis Study Group (1997 b) Visual function 5 years after optic neuritis. Arch Ophthalmol 115:1554–1562.
O’Riordan J, Thompson A, Kingsley D et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10–year follow–up. Brain 121:495–503.
Patterson VH, Heron JR (1980) Visual field abnormalities in multiple sclerosis. J Neurol Neurosurg Psychiat 43:205–208.
Paty DW, Ebers GC (1998) Multiple sclerosis. Davis FA, Philadelphia.
Perkin GD, Rose FC (1979) Optic neuritis and ist differential diagnosis. Oxford University Press, Oxford.
Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231.
Poser S (1984) Klinik der Multiplen Sklerose. Nervenheilk 3:53–58.
Purvin V (1998) Optic neuritis. Curr Opin Ophthal 9:3–9.
Rieckmann P, Toyka KV and the Austrian-German-Swiss Multiple Sclerosis Therapy’Consen–sus Group (MSTCG) (1999) Escalating immunotherapy of multiple sclerosis. Eur Neurol 42:121–127.
Rizzo JF, Lesell S (1988) Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long–term prospective study. Neurologie 38:185–190.
Rizzo JF, Lessell S (1991) Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 109:1668–1672.
Sailer M, O’Riordan J, Thompson A (1999) The prognostic value of brain MRI in clinically isolated syndromes suggestive of demyelination. Neurol 52:599–606.
Sandberg-Wollheim M, Bynke H, Cronqvist S et al. (1990) A long term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27:386–393.
Silverman SE, Hart WM, Gordon MO et al. (1990) Dyschromatopsia of optic neuritis is determined in part by the foveal/perfoveal distribution of visual field damage. Invest Opthalmol Vis Sci 31:1895–1902.
Slamovitis S, Rosen CE, Cheng KP et al. (1991) Visual recovery in patients with optic neuritis and visual loss to no light perception. Am J Ophthalmol 111:209–214.
Ulrich J, Groebke–Lorenz W (1983) The optic nerve in multiple sclerosis: a morphological study with retrospective clinicopathological correlations. Neurophthalmol 3:149–159
Ulrich J, Groebke–Lorenz W (1983) The optic nerve in multiple sclerosis: a morphological study with retrospective clinicopathological correlations. Neurophthalmol 3:149–159
Uhthoff W (1890) Untersuchungen iiber die bei der multiplen Herdsklerose vorkommenden Augenstorungen. Arch Psychiat Nervenkr 21:55–116, 303–410.
Wildberger H (1998) Optikusneuritis. In: Huber A, Kompf D (Hrsg) Klinische Neurophthalmologie. Thieme, Stuttgart New York, S 288–299.
Wikstrom J, Poser S, Ritter G (1980) Optic neuritis as an initial symptom in multiple sclerosis. Acta Neurol Scand 61:178–185.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Zettl, U.K., Dressler, D., Guthoff, R. (2001). Neuritis nervi optici und Multiple Sklerose. In: Zettl, U.K., Mix, E. (eds) Multiple Sklerose. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59453-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-59453-3_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-41121-5
Online ISBN: 978-3-642-59453-3
eBook Packages: Springer Book Archive